Danish pharmaceutical conglomerate Novo Nordisk is breaking the trend of recent consolidation in the world’s pharmaceutical industry, reports say, as the company instead is focusing on expanding its research and development staff.

According to reports, the firm holds a dominant market position in the diabetes treatment industry and has cash to …read more

Source: Global Competition Law Blogs